C75 trans

Catalog No.S8915 Batch:S891501

Print

Technical Data

Formula

C14H22O4
Molecular Weight 254.32 CAS No. 191282-48-1
Solubility (25°C)* In vitro DMSO 51 mg/mL (200.53 mM)
Ethanol 26 mg/mL (102.23 mM)
Water Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description C75 trans (trans-C75, (±)-C75) is a novel, potent synthetic inhibitor of fatty acid synthase (FAS/FASN) with IC50 of 35 μM and 50 μM in clonogenic assays and spheroid growth assay, respectively. C75 is used as a tool for studying fatty acid synthesis in metabolic disorders and cancer.
Targets
FASN [1]
(clonogenic assay)		 FASN [1]
(spheroid growth assay)
35 μM 50 μM
In vitro

C75 is toxic to prostate cancer cells. C75 reduces cell migration, while enhances radiation-induced clonogenic kill and enhances the spheroid growth delay induced by radiation exposure. Apoptosis induction by radiation exposure is enhanced by C75 treatment.[1] C75 inhibits fatty acid synthesis and growth of established cancer cell lines from neu-N transgenic mice. C75 reduces the proliferation and expression of FAS, neu, and related genes in mammary epithelium.[2]
In vivo

C75 inhibits fatty acid synthesis and in vivo mammary cancer development. C75 treatment prevents mammary cancer development and retards mammary development in neu-N transgenic mice.[2]

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    PC3 cells, LNCaP cells

  • Concentrations

    5 μM, 25 μM, 35 μM, 50 μM

  • Incubation Time

    3 h, 6 h, 24 h

  • Method

    PC3 cells are seeded in 25 cm2 flasks at 105 cells/flask. When cultures are in exponential growth phase, media is removed and replaced with fresh drug-containing media. Cells are then incubated for 24 h at 37℃ in 5% CO2. To determine optimal sequencing of therapeutic agents, three different combination treatment schedules are assessed: 1. radiation and C75 administered simultaneously; 2. radiation administered 24 h before C75; and 3. radiation administered 24 h after C75. After treatment, cells are seeded for clonogenic survival assay.
Animal Study:

[2]
  • Animal Models

    neu-N transgenic mice, FVB/N mice

  • Dosages

    30mg/kg

  • Administration

    IP

Selleck's C75 trans has been cited by 2 publications

Protein C receptor maintains cancer stem cell properties via activating lipid synthesis in nasopharyngeal carcinoma [ Signal Transduct Target Ther, 2022, 7(1):46] PubMed: 35169126
Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication [ Nat Metab, 2021, 10.1038/s42255-021-00479-4] PubMed: 34580494

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.